Breaking News Instant updates and real-time market news.

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

, DGII

Digi International

$15.10

0.33 (2.23%)

18:35
11/14/19
11/14
18:35
11/14/19
18:35

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Farfetch (FTCH) up 19.0%... Digi International (DGII) up 12.6%... Applied Materials (AMAT) up 3.8%... Kulicke and Soffa (KLIC) up 2.3%... Helmerich & Payne (HP) up 2.3%... Wheaton Precious Metals (WPM) up 2.0%. ALSO HIGHER: Radnet (RDNT) up 9.6% after entering S&P SmallCap 600 index... RH (RH) up 7.0% after Berkshire Hathaway disclosed new stake in company. DOWN AFTER EARNINGS: Aurora Cannabis (ACB) down 11.6%... Osmotica (OSMT) down 9.2%... Globant (GLOB) down 4.8%... Dolby Labs (DLB) down 3.8%... Nvidia (NVDA) down 1.4%. Movers as of 18:15ET.

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

DGII

Digi International

$15.10

0.33 (2.23%)

AMAT

Applied Materials

$56.89

-0.24 (-0.42%)

KLIC

Kulicke & Soffa

$25.18

-0.22 (-0.87%)

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

WPM

Wheaton Precious Metals

$26.47

-0.12 (-0.45%)

RDNT

RadNet

$15.92

0.09 (0.57%)

RH

RH

$175.19

1.98 (1.14%)

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

OSMT

Osmotica Pharmaceuticals

$4.00

-0.03 (-0.74%)

GLOB

Globant

$108.99

3.975 (3.79%)

DLB

Dolby

$65.56

-0.14 (-0.21%)

NVDA

Nvidia

$209.88

1.33 (0.64%)

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 06

    Jan

FTCH Farfetch
$7.49

-0.54 (-6.72%)

08/14/19
OPCO
08/14/19
NO CHANGE
Target $25
OPCO
Outperform
Farfetch price target lowered to $25 from $32 at Oppenheimer
Oppenheimer analyst Jason Helfstein lowered his price target for Farfetch to $25 from $32, while reiterating an Outperform rating on the shares as he believes the company should emerge in a stronger position following industry response to increased discounting by online luxury retailers and the benefits of the New Guards acquisition. The analyst notes that leading luxury brands now intend to limit online wholesale inventory over the next year to address excessive discounting. While this is positive for Farfetch in the long-term, it will take several quarters for these policy changes to work through the industry, he contends.
08/12/19
FBCO
08/12/19
NO CHANGE
Target $30
FBCO
Outperform
RealReal near-term visibility more limited, says Credit Suisse
RealReal's (REAL) near-term visibility is more limited ahead of the company's Q2 results given recent luxury read-throughs, Credit Suisse analyst Michael Binetti tells investors in a research note. Negative reads from Barney's bankruptcy and Farfetch's (FTCH) Q2 results brought RealReal's shares down 26% last week, Binetti tells investors in a research note. The analyst says the "significant compression" in digital marketplace multiples has made his $30 target price for RealReal well above the valuation of Farfetch (FTCH) and peers. However, Binetti still thinks RealReal can be a "key asset in retail stock portfolios." He believes the company has baked in some near-term revenue conservatism around the elevated industry promotions it already saw coming ahead of the initial public offering. Further, the analyst notes that in past periods of increased promos in the primary luxury space, RealReal has seen "unexpected positive lifts" to its new customer growth trends. Binetti keeps an Outperform rating on the shares.
11/13/19
BERN
11/13/19
DOWNGRADE
Target $4
BERN
Underperform
Farfetch downgraded to Underperform from Market Perform at Bernstein
Earlier, Bernstein analyst Luca Solca downgraded Farfetch to Underperform from Market Perform with a $4 price target, citing his view that the "viability of a business model focused on providing the most aggressive prices" is questionable in the luxury market.
11/04/19
GSCO
11/04/19
NO CHANGE
Target $21.4
GSCO
Buy
Farfetch price target lowered to $21.40 from $37 at Goldman Sachs
Goldman Sachs analyst Louise Singlehurst lowered her price target for Farfetch to $21.40 from $37 while maintaining a Buy rating on the shares. While promotional activity will likely remain near term, this is a temporary issue, not structural, Singlehurst tells investors in a research note. The analyst says shares of Farfetch are down 50% year-to-date due to concerns over growth, margin pressure and acquisition strategy. However, the demand for luxury sales online is growing, and E-Concessions will take most share among third-party platforms, which is a positive for Farfetch, says Singlehurst.
DGII Digi International
$15.10

0.33 (2.23%)

11/01/19
11/01/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Digi International (DGII) initiated with an Outperform at Baird. 2. Wave Life Sciences (WVE) initiated with a Buy at Guggenheim. 3. PPG (PPG) resumed with an Equal Weight at Morgan Stanley. 4. Homology Medicines (FIXX) initiated with a Perform at Oppenheimer. 5. Sarepta (SRPT) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/19
BARD
11/01/19
INITIATION
Target $19
BARD
Outperform
Digi International initiated with an Outperform at Baird
Baird analyst Richard Eastman initiated coverage of Digi International with an Outperform rating citing its focused IoT growth oriented platform. The analyst sees a significant runway for growth as the company builds a recurring SaaS business model. He sees the company scaling its Digi SmartSense platform which will enhance the customer value proposition which should be reflected in an increased franchise value. Eastman has a $19 price target on Digi International shares.
AMAT Applied Materials
$56.89

-0.24 (-0.42%)

11/12/19
COWN
11/12/19
NO CHANGE
Target $65
COWN
Outperform
Applied Materials price target raised to $65 from $55 at Cowen
Cowen analyst Krish Sankar raised his price target on Applied Materials to $65 from $55 ahead of earnings on Thursday. The analyst noted the stock's upward move since its last earnings report citing the strength in foundry/logic capital spending, along with positive results and commentary from customers and peers. He said he remains bullish on the name and called its his top semi-cap pick. Sankar reiterated his Outperform rating on Applied Materials shares.
11/12/19
WELS
11/12/19
NO CHANGE
Target $62
WELS
Outperform
Applied Materials price target raised to $62 from $58 at Wells Fargo
Wells Fargo analyst Joe Quatrochi raised his price target for Applied Materials to $62 from $68 ahead of the company's Q4 earnings report, saying shares already largely reflect an expectation of continued foundry/logic spending strength in Q4 and potential upside to the current Q1 consensus revenue estimate. Quatrochi tells investors in a research note that he thinks the company's commentary will continue to support the current consensus estimate calling for 2020 total revenue growth of ~11% y/y. The analyst reiterates an Outperform rating on the shares.
11/12/19
STFL
11/12/19
NO CHANGE
Target $67
STFL
Buy
Applied Materials price target raised to $67 from $57 at Stifel
Stifel analyst Patrick Ho raised his price target for Applied Materials to $67 from $57 and maintains a Buy rating on the shares ahead of the company's Q4 results. Large-cap names, like Applied Materials, deserve higher multiples, particularly when compared to other industrial names, Ho tells investors in a research note. The analyst expects a "more optimistic" tone on the company's earnings call, that sets up 2020 for an above-average growth year. Applied Materials remains Ho's top large cap name in his coverage universe.
10/29/19
DZBN
10/29/19
DOWNGRADE
Target $46
DZBN
Sell
Applied Materials downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Ingo Wermann downgraded Applied Materials to Sell from Hold with a $46 price target.
KLIC Kulicke & Soffa
$25.18

-0.22 (-0.87%)

07/08/19
DADA
07/08/19
DOWNGRADE
DADA
Neutral
Kulicke & Soffa downgraded to Neutral from Buy at DA Davidson
11/20/18
CHLM
11/20/18
INITIATION
Target $30
CHLM
Buy
Kulicke & Soffa initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Christian Schwab started Kulicke & Soffa with a Buy rating and $30 price target. The analyst notes that management believes the current business softness will be short term in nature, and revenues are expected to stabilize at current levels and accelerate meaningfully in the 2H of FY19. Schwab believes the company's significant cash balance and meaningful multi-year earnings potential create an attractive risk/reward.
07/08/19
07/08/19
DOWNGRADE

Neutral
Semiconductor Capital Equipment group cut to Neutral at DA Davidson on valuation
As previously reported, DA Davidson analyst Thomas Diffely cut his ratings on Lam Research (LRCX), Kulicke and Soffa (KLIC), Ichor Holdings (ICHR), Applied Materials (AMAT), and Advanced Energy Services (AEIS) to Neutral from Buy as part of his broader research note downgrading the Semiconductor Capital Equipment group following its "significant" year-to-date appreciation. The analyst cites the delayed recovery in memory along with the "cycle uncertainty" in assigning more "conservative" valuation multiples to these stocks and believes that their risk-reward profiles look "fairly balanced" at current levels. Diffely also lowers his price target on Lam Research to $200 from $225, Kulicke and Soffa to $26 from $30, Ichor Holdings to $25 from $32, Applied Materials to $45 from $55, and Advanced Energy Services to $55 from $60.
11/20/18
DADA
11/20/18
NO CHANGE
Target $32
DADA
Buy
Kulicke & Soffa price target lowered to $32 from $35 at DA Davidson
DA Davidson analyst Thomas Diffely lowered his price target on Kulicke & Soffa to $32 and also lowered his FY19 EPS view to $1.70 from $2.25, saying the weakness in China is accentuating its seasonal dip. The analyst cites the trade war uncertainty impacting current activity levels in China, along with the continued oversupply of NAND memory, and the recent buildout in capacity based on several strong quarters of shipments. The analyst also keeps his Buy rating on Kulicke & Soffa longer term, saying its fundamentals should "remain strong in the emerging data driven economy" and sees the "seemingly insatiable thirst for data and the resulting proliferation of chips and sensors" continue to drive the company's core, unit driven, wire bonding business for some time.
HP Helmerich & Payne
$39.30

0.04 (0.10%)

09/30/19
SBSH
09/30/19
DOWNGRADE
Target $43
SBSH
Neutral
Helmerich & Payne downgraded to Neutral from Buy at Citi
Citi analyst Scott Gruber downgraded Helmerich & Payne to Neutral from Buy and lowered his price target for the shares to $43 from $50. The analyst recently cut his 2020 U.S. rig count forecast, which now calls for a 5% year-over-year decline next year. Falling utilization across both super spec and standard rig classes likely weigh on pricing, Gruber tells investors in a research note. The analyst adds that despite the recent pullback in shares of land drillers, his estimates are now ~30% below consensus for 2020.
10/08/19
BOFA
10/08/19
DOWNGRADE
BOFA
Neutral
Helmerich & Payne downgraded to Neutral from Buy at BofA/Merrill
10/08/19
BOFA
10/08/19
DOWNGRADE
BOFA
BofA sees more weakness ahead for U.S. land drillers, downgrades four stocks
As previously reported, BofA Merrill Lynch analyst Chase Mulvehill downgraded Helmerich & Payne (HP) and Patterson-UTI (PTEN), each to Neutral from Buy, and downgraded Nine Energy Services (NINE) and FTS International (FTSI), each to Underperform from Neutral. Mulvehill said capital discipline and service efficiency gains from U.S. E&P comapnies is leading to intensifying weakness across the Oil Field Services sector, driving activity that has been even worse than his already more cautious view. He also sees it as increasingly likely that 2020 will be another year of spending contraction for U.S. explorers and producers. For the two stocks he cut to Underperform, Mulvehill additionally cited the companies' levered balance sheets.
10/08/19
10/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oracle (ORCL), Carbonite (CARB), and Check Point (CHKP) downgraded to Hold from Buy at Jefferies. 2. TerraForm Power (TERP) downgraded to Equal Weight from Overweight at Barclays. 3. Puma Biotechnology (PBYI) downgraded to Sell from Neutral at Goldman Sachs while Nektar Therapeutics (NKTR) was double downgraded to Sell from Buy. 4. Qiagen (QGEN) downgraded to Underweight from Neutral at JPMorgan and to Equal Weight from Overweight at Barclays. 5. Helmerich & Payne (HP) and Patterson-UTI (PTEN) downgraded to Neutral from Buy at BofA/Merrill. Nine Energy Services (NINE) and FTS International (FTSI) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WPM Wheaton Precious Metals
$26.47

-0.12 (-0.45%)

10/15/19
LEHM
10/15/19
DOWNGRADE
LEHM
Equal Weight
Barclays downgrades Kinross Gold, Wheaton Precious Metals on valuation
Barclays analyst Matthew Murphy downgraded both Kinross Gold (KGC) and Wheaton Precious Metals (WPM) to Equal Weight from Overweight ahead of the Q3 earnings season. The analyst, who admits fundamentals for the precious metal miners continue to improve, sees valuations in the North America Metals and Mining space as "quite full." He cites valuation for both downgrades.
07/23/19
07/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Devon Energy (DVN) reinstated with a Sell from Neutral at Goldman Sachs with analyst Brian Singer saying the stock's year-to-date outperformance relative to peers is "overdone" as the remaining sum-of-the-parts valuation for the shares is "too rich" following the sale of its Canadian business. 2. Sprouts Farmers Market (SFM) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh citing his assessment of potentially more muted profit growth going forward coupled with increasing uncertainty on the management and competitive fronts. 3. Viveve (VIVE) double downgraded to Underperform from Buy at Mizuho, downgraded to Hold from Buy at Stifel and to Market Perform from Outperform at Raymond James. 4. Wheaton Precious Metals (WPM) downgraded to Hold from Buy at GMP Securities. 5. Cadence Bancorp (CADE) downgraded to Neutral from Buy at Goldman Sachs and to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/23/19
MITR
07/23/19
DOWNGRADE
MITR
Hold
Wheaton Precious Metals downgraded to Hold from Buy at GMP Securities
10/15/19
LEHM
10/15/19
DOWNGRADE
LEHM
Equal Weight
Wheaton Precious Metals downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Matthew Murphy downgraded Wheaton Precious Metals to Equal Weight from Overweight with a price target of C$37.05.
RDNT RadNet
$15.92

0.09 (0.57%)

03/15/19
RAJA
03/15/19
DOWNGRADE
RAJA
Outperform
RadNet downgraded to Outperform from Strong Buy at Raymond James
01/04/19
JEFF
01/04/19
NO CHANGE
JEFF
Jefferies more cautious on Healthcare Services group for 2019
After strong performance in 2018, Jefferies analyst Brian Tanquilut is more cautious on the Healthcare Services group for 2019 given his belief that sales growth will be "tepid" for most providers as overall utilization flattens out and increased market volatility drives greater scrutiny of debt levels. Given this backdrop, companies that can deliver positive organic or acquisition-driven growth with solid balance sheets should outperform, Tanquilut tells investors in a research note. His top picks in the space are Addus HomeCare (ADUS), Amedisys (AMED), AMN Healthcare (AMN), Encompass Health (EHC), HCA Healthcare (HCA), LHC Group (LHCG) and RadNet (RDNT).
03/15/19
03/15/19
DOWNGRADE
Target $17.5

Outperform
RadNet downgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James downgraded RadNet to Outperform from Strong Buy and raised its price target to $17.50 from $16. Analyst John Ransom said the +14% move up in shares following the strong Q4 report and guidance causes him to take a more modest stance.
RH RH
$175.19

1.98 (1.14%)

10/08/19
WOLF
10/08/19
INITIATION
Target $197
WOLF
Peer Perform
RH assumed with a Peer Perform rating at Wolfe Research
Wolfe Research analyst Chris Bottiglieri assumed coverage of RH with a Peer Perform rating and $197 price target.
09/16/19
LOOP
09/16/19
NO CHANGE
Target $190
LOOP
Buy
RH price target raised to $190 from $180 at Loop Capital
Loop Capital analyst Anthony Chukumba raised his price target on RH to $190 and kept his Buy rating after the company's completed convertible note offering last week. The analyst says he is impressed with RH's ability to issue debt without any cash interest cost, which highlights investors' confidence in the company's long-term potential.
11/12/19
LEHM
11/12/19
INITIATION
Target $198
LEHM
Overweight
RH initiated with an Overweight at Barclays
Barclays analyst Adrienne Yih initiated coverage of RH with an Overweight rating and $198 price target. The analyst is positive on the company's business model that is already more than 90% direct-to-consumer and the strength of its brand limiting discounting. Yih adds that RH is benefiting from the shift in the inventory model away from high "in-stock" levels to a more customizable, build-to-order inventory model.
09/19/19
WELS
09/19/19
NO CHANGE
Target $195
WELS
Outperform
RH price target raised to $195 from $175 at Wells Fargo
Wells Fargo analyst Zachary Fadem raised his price target for RH to $195 from $175 to reflect the closing of the company's $350M convertible note offering. The analyst reiterates an Outperform rating on the shares.
ACB Aurora Cannabis
$3.29

-0.25 (-7.06%)

11/11/19
MKMP
11/11/19
NO CHANGE
MKMP
Canopy Growth, Aurora Cannabis price targets lowered at MKM Partners
MKM Partners analyst Bill Kirk kept his Neutral rating on Canopy Growth (CGC) while lowering its price target to CAD30 from CAD33 and also kept his Sell rating with an unchanged CAD3.50 price target on Aurora Cannabis (ACB) ahead of their earnings reports this Thursday. The analyst says that neither company is expected to show much improvement on the top line, with inventory held at provinces weighing on shipments, pricing coming down, and the price premium relative to "illicit channels" widening. Kirk adds that the likely earnings disappointment may result in the bulls "revisiting the industry's path and pace toward profitability."
11/05/19
BOFA
11/05/19
NO CHANGE
BOFA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
BofA Merrill Lynch analyst Christopher Carey noted that Mexico's Supreme Court has granted an extension until April 30, 2020 for Congress to legalize all forms of cannabis, writing in its decision that considering the complexity of the issue it grants the extension "exceptionally and for one time only." He views this as an important development for the industry since, in addition to opening a potentially large market, it will put even more pressure on U.S. federal action as the country will potentially "place the US between 2 of only 3 countries in the world to have legalized cannabis for recreational use." 9% of Mexico's population of 131M is estimated to have consumed cannabis in 2018 and the legal market could be worth $1B by 2024, according to BDS Analytics, noted Carey. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Trulieve Cannabis (TCNNF).
11/05/19
CANT
11/05/19
INITIATION
CANT
Neutral
Aurora Cannabis initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Aurora Cannabis with a Neutral rating and price target of C$5.10. The analyst expects the Canadian licensed producer group to rally in the coming months on "more positive than negative catalysts," but he sees more upside in other stocks at this time.
11/04/19
CANT
11/04/19
INITIATION
CANT
Neutral
Aurora Cannabis initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Aurora Cannabis with a Neutral rating and C$5.10 price target.
OSMT Osmotica Pharmaceuticals
$4.00

-0.03 (-0.74%)

08/12/19
JEFF
08/12/19
NO CHANGE
Target $10
JEFF
Buy
Osmotica shares discounting late-stage pipeline, says Jefferies
With a "very low" $170M market capitalization, Osmotica Pharmaceuticals shares are discounting nearly all of the prospects for its two late-stage pipeline candidates - Ontinua ER and RVL-1201, potentially the first ever FDA approved non-surgical therapy for blepharoptosis, Jefferies analyst David Steinberg tells investors in a research note. The analyst lowered his price target for the shares to $10 from $13 and keeps a Buy rating on the name.
03/28/19
WELS
03/28/19
NO CHANGE
Target $14
WELS
Outperform
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
Wells Fargo analyst David Maris lowered his price target for Osmotica Pharmaceuticals to $14 from $17.50 following the company's Q4 results. The stock in morning trading is down 38%, or $2.56, to $4.18. Osmotica used the Q4 results to report "mixed" results from its arbaclofen, or Ontinua, study, Maris tells investors in a research note. Arbaclofen did not demonstrate superiority to placebo as measured by the Clinical Global Impression of Change, but did demonstrate statistical significance in spasticity relative to placebo when using the Total Numeric modified Ashworth Scale, says Maris. He points out that Osmotica continues to advance RVL-1201 for blepharotosis, and remains on track to report results by mid-year. The analyst pushed out the Ontinua launch from 2020 to 2021 and reduced his sales estimates due to approvability risks. His 2023 sales forecast for Ontinua is now $60M, down from $120M previously. Maris keeps an Outperform rating on Osmotica. Though the Q4 earnings report was "disappointing" given the negative arbaclofen results, the company trades at less than seven times estimated 2019 enterprise value to EBITDA with positive cash flow, the analyst tells investors in a research note.
06/11/19
LEHM
06/11/19
NO CHANGE
Target $11
LEHM
Overweight
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
Barclays analyst Balaji Prasad took over coverage of Osmotica Pharmaceuticals and keep an Overweight rating on the shares with a reduced price target of $11.
GLOB Globant
$108.99

3.975 (3.79%)

10/21/19
KEYB
10/21/19
UPGRADE
Target $114
KEYB
Overweight
Globant upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Arvind Ramnani upgraded Globant to Overweight from Sector Weight with a $114 price target.
09/10/19
HSBC
09/10/19
DOWNGRADE
HSBC
Reduce
Globant downgraded to Reduce from Hold at HSBC
HSBC analyst Christopher Recouso downgraded Globant to Reduce from Hold and raised his price target to $80 from $52.
10/21/19
10/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. HP Enterprise (HPE) double-upgraded to Buy from Underperform at BofA/Merrill with analyst Wamsi Mohan saying the company's underlying trends are improving. 2. CubeSmart (CUBE) upgraded to Strong Buy from Outperform at Raymond James with analyst Jonathan Hughes saying he believes Q3 results will be "positive" following what was likely a strong summer leasing season. 3. Consolidated Edison (ED) upgraded to In Line from Underperform at Evercore ISI. 4. Globant (GLOB) upgraded to Overweight from Sector Weight at KeyBanc with analyst Arvind Ramnani saying after recently meeting with management, he has a greater appreciation of its overall growth drivers, and increased margin stability. 5. Gildan Activewear (GIL) upgraded to Hold from Sell at Desjardins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/19
KEYB
10/21/19
UPGRADE
Target $114
KEYB
Overweight
Globant upgraded to Overweight at KeyBanc
As previously reported, KeyBanc analyst Arvind Ramnani upgraded Globant to Overweight from Sector Weight with a $114 price target. Having recently met with management, the analyst has a greater appreciation of its overall growth drivers, and increased margin stability. He expects overall growth of 20%-plus will be driven in the near-term by its established expertise in Digital, Cloud, Analytics, etc., and long-term by investments in its AI/Automation offerings. Further, its diversification and currency hedging have resulted in a more stable margin profile, which should lead to more consistent EPS growth, he contends.
DLB Dolby
$65.56

-0.14 (-0.21%)

08/02/19
WBLR
08/02/19
NO CHANGE
WBLR
Outperform
Dolby core licensing business remains intact, says William Blair
Shares of Dolby Laboratories are trading down after the company lowered full-year revenue guidance and announced an unexpected restructuring charge this quarter, William Blair analyst Ralph Schackart tells investors in a research note. However, Dolby posted a 3% beat on licensing revenues for the second quarter in a row, adds the analyst. He remains bullish on Dolby and believes its core licensing business is intact. Schackart keeps an Outperform rating on the shares.
08/02/19
RILY
08/02/19
UPGRADE
RILY
Buy
Dolby upgraded to Buy from Neutral at B. Riley FBR
08/02/19
RILY
08/02/19
UPGRADE
Target $73
RILY
Buy
B. Riley FBR upgrades Dolby amid today's selloff, sees 22% upside
B. Riley FBR analyst Eric Wold upgraded Dolby Laboratories to Buy from Neutral and raised his price target for the shares to $73 from $67. The analyst sees 22% upside potential given today's post-earnings selloff. The stock in late morning trading is down 12%, or $8.34, to $59.74. Wold is "increasingly optimistic" on Dolby's improving penetration rates for its audio/visual technologies and highlights its accelerated share repurchases.
05/31/19
DOTC
05/31/19
NO CHANGE
DOTC
Buy
Recent developments point to continued Dolby ecosystem expansion, says Dougherty
Dougherty analyst Steven Frankel noted that Vizio recently unveiled its Holiday 2019 TV line-up, "with Dolby Vision featured from top to bottom," that the recently released One Plus 7 smartphone includes Atmos, and that Dell has recently upgraded its Dolby Vision enabled XP 13 notebook. Additionally, Apple's (AAPL) iTunes continues to extend its catalog of Vision and Atmos content, according to Frankel, who sees the company's ability to drive a "virtuous circle of content and devices" embedded with its technologies as core to Dolby's (DLB) success. He keeps a Buy rating on Dolby shares.
NVDA Nvidia
$209.88

1.33 (0.64%)

11/14/19
BMOC
11/14/19
NO CHANGE
Target $200
BMOC
Market Perform
Nvidia price target raised to $200 from $145 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Nvidia to $200 ahead of its Q3 earnings later today, saying the setup going into the print is "relatively positive" with a "cleaned up" supply chain in the Gaming segment and recovery among other chip companies supporting expectations for the Data Center segment. The analyst adds that he is "playing catch-up" with the target price but also maintains his Market Perform rating, noting that the stock is reasonably valued at current levels.
11/12/19
SUSQ
11/12/19
NO CHANGE
Target $240
SUSQ
Positive
Nvidia price target raised to $240 from $190 at Susquehanna
Susquehanna analyst Christopher Rolland raised his price target for Nvidia (NVDA) to $240 from $190 ahead of the company's Q3 results on November 14. While difficult to make a clear call on the quarter, this is the first time in many quarters that expectations are generally in-check with typical seasonality, Rolland tells investors in a pre-research note. He points out that Nvidia in the quarter refreshed its high-end RTX cards to combat the 7nm graphics processing unit launch from AMD (AMD). While AMD was able to gain modest share in aftermarket graphics cards during the quarter and is now rumored to be launching a lower-priced Navi GPU to compete in the midrange, the analyst believes Nvidia will take back most lost share on the release of 7nm next year. With the company facing "the most reasonable Street expectations in quite some time," Rolland reiterates a Positive rating on Nvidia.
11/11/19
DBAB
11/11/19
NO CHANGE
Target $190
DBAB
Hold
Nvidia price target raised to $190 from $160 at Deutsche Bank
Deutsche Bank analyst Ross Seymore raised his price target for Nvidia to $190 from $160 ahead of the company's Q3 results and keeps a Hold rating on the shares. With the stock up 30% since the company's last earnings report, investors are expecting a "solid beat/raise heading into earnings," Seymore tells investors in a research note. He sees potential for "modest" upside relative to expectations but believes "much of this goodness is already reflected in the shares."
11/12/19
OPCO
11/12/19
NO CHANGE
Target $250
OPCO
Outperform
Nvidia price target raised to $250 from $190 at Oppenheimer
Oppenheimer analyst Rick Schafer raised his price target for Nvidia to $250 from $190 ahead of its quarterly earnings, saying he expects a beat and raise set up for Q3. In a research note to investors, Schafer, who maintains an Outperform rating, says he sees upside led by continued post-crypto rebound in core gaming as well as improved hyperscaler spend on DC/Cloud and adds that he remains a buyer of Nvidia, as the company appears positioned to capitalize on long-term secular trends in DC, high performance gaming, and autonomous vehicles.

TODAY'S FREE FLY STORIES

KYKOF

Kyowa Kirin

$0.00

(0.00%)

07:57
12/09/19
12/09
07:57
12/09/19
07:57
Initiation
Kyowa Kirin initiated  »

Kyowa Kirin initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$44.80

0.335 (0.75%)

07:57
12/09/19
12/09
07:57
12/09/19
07:57
Recommendations
Pentair analyst commentary  »

Pentair price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

07:56
12/09/19
12/09
07:56
12/09/19
07:56
Initiation
Daiichi Sankyo initiated  »

Daiichi Sankyo initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:55
12/09/19
12/09
07:55
12/09/19
07:55
Conference/Events
Agios Pharmaceuticals to hold an investor reception »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ARQL

ArQule

$9.67

0.15 (1.58%)

07:55
12/09/19
12/09
07:55
12/09/19
07:55
Conference/Events
ArQule to hold an investor conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

THRM

Gentherm

$44.25

0.4 (0.91%)

07:54
12/09/19
12/09
07:54
12/09/19
07:54
Initiation
Gentherm initiated  »

Gentherm resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$59.85

0.28 (0.47%)

07:53
12/09/19
12/09
07:53
12/09/19
07:53
Recommendations
TJX analyst commentary  »

TJX price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISTR

Investar Holding

$25.55

0.73 (2.94%)

07:51
12/09/19
12/09
07:51
12/09/19
07:51
Downgrade
Investar Holding rating change  »

Investar Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$39.58

0.86 (2.22%)

07:50
12/09/19
12/09
07:50
12/09/19
07:50
Downgrade
FB Financial rating change  »

FB Financial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$353.99

8.295 (2.40%)

07:49
12/09/19
12/09
07:49
12/09/19
07:49
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$233.74

0.3 (0.13%)

, BGNE

BeiGene

$186.89

-2.3 (-1.22%)

07:47
12/09/19
12/09
07:47
12/09/19
07:47
Recommendations
Amgen, BeiGene analyst commentary  »

Amgen price target raised…

AMGN

Amgen

$233.74

0.3 (0.13%)

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

AMTD

TD Ameritrade

$51.12

0.32 (0.63%)

, SCHW

Charles Schwab

$48.95

0.22 (0.45%)

07:45
12/09/19
12/09
07:45
12/09/19
07:45
Downgrade
TD Ameritrade, Charles Schwab rating change  »

TD Ameritrade shares…

AMTD

TD Ameritrade

$51.12

0.32 (0.63%)

SCHW

Charles Schwab

$48.95

0.22 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

07:45
12/09/19
12/09
07:45
12/09/19
07:45
Recommendations
International Flavors, DuPont analyst commentary  »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBIO

Mustang Bio

$3.86

0.025 (0.65%)

07:44
12/09/19
12/09
07:44
12/09/19
07:44
Hot Stocks
Mustang Bio: Lentiviral gene therapy with busulfan conditioning 'well tolerated' »

Mustang Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

07:44
12/09/19
12/09
07:44
12/09/19
07:44
Recommendations
Bluebird Bio analyst commentary  »

Bluebird Bio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AM

Antero Midstream

$4.49

-0.025 (-0.55%)

, AR

Antero Resources

$2.18

0.09 (4.31%)

07:43
12/09/19
12/09
07:43
12/09/19
07:43
Hot Stocks
Antero Midstream to purchase $100M of shares from Antero Resources »

Antero Midstream (AM)…

AM

Antero Midstream

$4.49

-0.025 (-0.55%)

AR

Antero Resources

$2.18

0.09 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCN

FTI Consulting

$111.68

0.28 (0.25%)

07:42
12/09/19
12/09
07:42
12/09/19
07:42
Hot Stocks
FTI Consulting enters partnership with Brainspace »

FTI Consulting announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$33.03

0.8 (2.48%)

07:41
12/09/19
12/09
07:41
12/09/19
07:41
Hot Stocks
BridgeBio appoints Eli Wallace as chief scientific officer for oncology »

BridgeBio Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

07:40
12/09/19
12/09
07:40
12/09/19
07:40
Recommendations
Alphabet Class A analyst commentary  »

Alphabet shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
12/09/19
12/09
07:40
12/09/19
07:40
General news
Treasury Market Outlook: equities have dipped lower in quiet trade »

Treasury Market Outlook:…

EPD

Enterprise Products

$26.25

0.18 (0.69%)

, ENB

Enbridge

$38.52

0.015 (0.04%)

07:39
12/09/19
12/09
07:39
12/09/19
07:39
Hot Stocks
Enterprise Products, Enbridge sign LOI to jointly develop deepwater terminal »

Enterprise Products…

EPD

Enterprise Products

$26.25

0.18 (0.69%)

ENB

Enbridge

$38.52

0.015 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

BLK

BlackRock

$495.78

5.6 (1.14%)

07:39
12/09/19
12/09
07:39
12/09/19
07:39
Conference/Events
BlackRock management to meet with Oppenheimer »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 26

    Feb

HBIO

Harvard Bioscience

$2.95

0.01 (0.34%)

07:38
12/09/19
12/09
07:38
12/09/19
07:38
Downgrade
Harvard Bioscience rating change  »

Harvard Bioscience…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.19

-0.01 (-0.84%)

07:37
12/09/19
12/09
07:37
12/09/19
07:37
Hot Stocks
Sesen Bio initiates rolling submission of BLA for Vicinium to FDA »

Sesen Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$59.81

0.89 (1.51%)

07:36
12/09/19
12/09
07:36
12/09/19
07:36
Conference/Events
Brunswick management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.